These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 26186631

  • 1. Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: propensity score-matched analysis.
    Ji MS, Jeong MH, Ahn YK, Kim SH, Kim YJ, Chae SC, Hong TJ, Seong IW, Chae JK, Kim CJ, Cho MC, Rha SW, Bae JH, Seung KB, Park SJ, Hur SH, Korea Acute Myocardial Infarction Registry Investigators.
    Int J Cardiol; 2015 Nov 15; 199():53-62. PubMed ID: 26186631
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Bae JW, Woo SI, Park JS, Jin DK, Jeon DW, Oh SK, Park JS, Kim DI, Hyon MS, Jeon HK, Lim DS, Kim MG, Rha SW, Her SH, Hwang JY, Kim S, Choi YJ, Kang JH, Moon KW, Jang Y, Kim HS.
    Am J Cardiol; 2014 Nov 01; 114(9):1329-38. PubMed ID: 25217457
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S, RESOLUTE All-Comers Investigators.
    J Am Coll Cardiol; 2014 Apr 29; 63(16):1617-25. PubMed ID: 24530680
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.
    Park KW, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, Kang HJ, Koo BK, Cho J, Gwon HC, Lee SY, Chae IH, Youn TJ, Chae JK, Han KR, Yu CW, Kim HS.
    J Am Coll Cardiol; 2013 Feb 05; 61(5):536-44. PubMed ID: 23273394
    [Abstract] [Full Text] [Related]

  • 10. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR).
    Kim Y, Oh SS, Jeong MH, Ahn Y, Kim JH, Hong YJ, Sim DS, Kim MC, Kim HS, Yun KH, Oh SK, Kim CJ, Cho MC.
    Cardiol J; 2019 Feb 05; 26(5):469-476. PubMed ID: 29745969
    [Abstract] [Full Text] [Related]

  • 11. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
    Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Shin DH, Kim JS, Ko YG, Choi D, Hong MK, Jang Y.
    Heart Vessels; 2019 Feb 05; 34(2):237-250. PubMed ID: 30167772
    [Abstract] [Full Text] [Related]

  • 12. One-year clinical outcomes of everolimus- versus sirolimus-eluting stents in patients with acute myocardial infarction.
    Chen KY, Rha SW, Wang L, Li YJ, Li GP, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Chae SC, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim HS, Kim CJ, Yoon JH, Ahn TH, Chung WS, Seung KB, Park SJ, Korea Acute Myocardial Infarction Registry Investigators.
    Int J Cardiol; 2014 Oct 20; 176(3):583-8. PubMed ID: 25305704
    [Abstract] [Full Text] [Related]

  • 13. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, Buszman PE, Kelbæk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Van Remortel E, Ronden J, Windecker S.
    JACC Cardiovasc Interv; 2011 Apr 20; 4(4):432-41. PubMed ID: 21511223
    [Abstract] [Full Text] [Related]

  • 14. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
    Patra S, Chakraborty RN, Pande A, Banerjee S, Jena M, Mandal PC, De SK, Khan A, Das SS, Ghosh D, Nag R.
    Cardiovasc Revasc Med; 2017 Apr 20; 18(3):160-164. PubMed ID: 28017259
    [Abstract] [Full Text] [Related]

  • 15. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW, Kang SH, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Hur SH, Ryu JK, Lee BR, Park YW, Chae IH, Kim HS, HOST–ASSURE Investigators.
    J Am Coll Cardiol; 2014 Jul 01; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [Abstract] [Full Text] [Related]

  • 16. Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea.
    Lee JM, Youn TJ, Park JJ, Oh IY, Yoon CH, Suh JW, Cho YS, Cho GY, Chae IH, Choi DJ.
    BMC Cardiovasc Disord; 2013 Sep 08; 13():65. PubMed ID: 24011332
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH.
    J Am Coll Cardiol; 2012 Apr 10; 59(15):1350-61. PubMed ID: 22341737
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M, Dörig M, Frangieh AH, Ghadri JR, Cammann VL, Diekmann J, Napp LC, D'Ascenzo F, Imori Y, Obeid S, Maier W, Lüscher TF, Templin C.
    Catheter Cardiovasc Interv; 2016 Nov 15; 88(6):E173-E182. PubMed ID: 27377554
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
    Piccolo R, Stefanini GG, Franzone A, Spitzer E, Blöchlinger S, Heg D, Jüni P, Windecker S.
    Circ Cardiovasc Interv; 2015 Apr 15; 8(4):. PubMed ID: 25858975
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
    Omar A, Torguson R, Kitabata H, Pendyala LK, Loh JP, Magalhaes MA, Satler LF, Suddath WO, Pichard AD, Waksman R.
    Catheter Cardiovasc Interv; 2014 Dec 01; 84(7):1053-60. PubMed ID: 24619969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.